Back to Search Start Over

Capizzi Vs HDMTX in the Intermediate Maintenance Phase in Patients with Intermediate-Risk ALL in a 3rd Level Hospital in Northeastern Mexico

Authors :
Fuentes, Valeria
Jimenez-Antolinez, Yajaira Valentina
Romero-Jacobo, Ginna Mariana
Garcia - Maldonado, Paulina
Ruiz-Padilla, Juan Pablo
Rodriguez- Miranda, Samantha Carolina
Marcos-Garcia, Jorge Federico
Colunga Pedraza, Julia Esther
Gomez-Almaguer, David
Gonzalez Llano, Oscar
Source :
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p5883-5883, 1p
Publication Year :
2023

Abstract

INTRODUCTION:Methotrexate is a fundamental drug in the treatment of acute lymphoblastic leukemia (ALL), playing an important role in CNS prophylaxis. Two strategies of methotrexate intensification have been studied: high-dose regimens (with leucovorin salvage) and Capizzi regimen (escalating doses, without salvage, with addition of L-asparaginase). Fifty-five percent of pediatric patients with ALL in Mexico are treated in general hospitals, with limited hospital bed availability, which may represent a deferral of treatment. We wanted to explore a feasible, economical and accessible ambulatory scheme, which may represent an option for those centers that do not have the infrastructure for maintenance with HDMTX.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
142
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs67815726
Full Text :
https://doi.org/10.1182/blood-2023-190990